Academic Journal
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
| العنوان: | Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. |
|---|---|
| المؤلفون: | Bassi, Jessica, Giannini, Olivier, Silacci-Fregni, Chiara, Pertusini, Laura, Hitz, Paolo, Terrot, Tatiana, Franzosi, Yves, Muoio, Francesco, Saliba, Christian, Meury, Marcel, Dellota, Exequiel A, Dillen, Josh R, Hernandez, Patrick, Czudnochowski, Nadine, Cameroni, Elisabetta, Beria, Nicola, Ventresca, Mariangela, Badellino, Alberto, Lavorato-Hadjeres, Soraya, Lecchi, Elisabetta, Bonora, Tecla, Mattiolo, Matteo, Trinci, Guido, Garzoni, Daniela, Bonforte, Giuseppe, Forni-Ogna, Valentina, Giunzioni, Davide, Berwert, Lorenzo, Gupta, Ravindra K, Ferrari, Paolo, Ceschi, Alessandro, Cippà, Pietro, Corti, Davide, Lanzavecchia, Antonio, Piccoli, Luca |
| المصدر: | nlmid: 101285081 ; essn: 1932-6203 |
| بيانات النشر: | Public Library of Science (PLoS) //doi.org/10.1371/journal.pone.0263328 PLoS One |
| سنة النشر: | 2022 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Animals, Antibodies, Neutralizing, Antibody Affinity, CHO Cells, COVID-19 Vaccines, Case-Control Studies, Cricetulus, Dose-Response Relationship, Immunologic, Follow-Up Studies, HEK293 Cells, Humans, Immunoglobulin G, Neutralization Tests, Renal Dialysis, Risk Factors, SARS-CoV-2, Vaccination, mRNA Vaccines |
| الوصف: | Funder: Swiss Kidney Foundation ; Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | https://www.repository.cam.ac.uk/handle/1810/334948 |
| DOI: | 10.17863/CAM.82386 |
| الاتاحة: | https://www.repository.cam.ac.uk/handle/1810/334948 https://doi.org/10.17863/CAM.82386 |
| Rights: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.769D2257 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.82386 |
|---|